ORIC Pharma reports Q4 2022 cash of $228.2M; Pfizer invests $25M; Phase 1b data expected H2 2023

Oric Pharmaceuticals, Inc.

Cash and investments $228.2M at Dec 31, 2022; runway into first half of 2025.
Pfizer purchased 5.4M shares at $4.65/share for $25M equity investment; collaboration on ORIC-533 + elranatamab combo.
R&D expenses $16.3M in Q4 2022 vs $16.7M in Q4 2021; full-year R&D $61.7M vs $56.9M.
Initial Phase 1b data for ORIC-533, ORIC-114, and ORIC-944 expected in second half of 2023.
Selected a PLK4 inhibitor development candidate; Jeff Settleman (Pfizer) joined Scientific Advisory Board.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Oric Pharmaceuticals, Inc. reported financial results for fourth quarter and full year ended December 31, 2022.

Period: fourth quarter and full year ended December 31, 2022
Result: reported results

Exact text from the filing

ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today reported financial results and operational updates for the quarter and year ended December 31, 2022.

View on SEC.gov

Browse all earnings releases →

Oric Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-008457

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.